Related Experiment Videos
[Influence of ACE inhibitor spirapril on left ventricular hypertrophy]
U Arend1, S Albrecht, E Meisel
1Klinische Pharmakotherapie, Dresden. ute.arend@web.de
Insights
Spirapril effectively reversed left ventricular hypertrophy (LVH) in hypertensive patients. This ACE inhibitor significantly reduced left ventricular mass index (LVMI) over six months, improving cardiac health.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) affects 15-30% of essential hypertension patients.
- LVH increases risk of myocardial infarction, heart failure, and sudden cardiac death.
- Reversing LVH is a key treatment goal, with ACE inhibitors being suitable.
Purpose of the Study:
- To investigate the efficacy of spirapril in reversing LVH.
- To assess the impact of spirapril on left ventricular mass index (LVMI) and diastolic wall thickness.
Main Methods:
- Open, bicentric study of 37 hypertensive patients with confirmed LVH.
- Echocardiography used to measure LVMI and diastolic wall thickness.
- Treatment duration of 3 and 6 months.
Main Results:
- LVMI decreased by 14.7% after 3 months and 27.3% after 6 months.
- Spirapril's effect was consistent whether used alone or with other antihypertensives.
- The long-lasting effect of spirapril may contribute to these results.
Conclusions:
- Spirapril is effective in reversing left ventricular hypertrophy in hypertensive patients.
- The study highlights the potential of spirapril in managing LVH and associated cardiovascular risks.
Background:
In view of the prevalence of left ventricular hypertrophy (LVH) in patients with essential hypertension, (15-30%), with an increased risk (2-4 x) of developing myocardial infarction, heart failure or malignant arrhythmia, possibly even leading to sudden cardiac death, effective reversal of LVH is a major aim of treatment. For this purpose, angiotensin-converting enzyme (ACE) inhibitors have proved to be most suitable.
Method:
In an open bicentric study involving 37 hypertensive patients with LVH confirmed by echocardiography, the effect of spirapril in reversing the left ventricular mass index (LVMI) and diastolic left ventricular wall thickness was investigated after 3 and 6 months.
Results:
The LVMI decreased by 14.7% after 3, and by 27.3% after 6 months, irrespective of whether spirapril was given alone or in addition to other antihypertensive pre-medication. The results may be due to the proven 24-hour effect of spirapril in conjunction with the very long half-life.